Travere Therapeutics Inc. (TVTX)
19.75
-1.65 (-7.71%)
At close: Mar 03, 2025, 3:59 PM
19.80
0.28%
After-hours: Mar 03, 2025, 04:05 PM EST
Travere Therapeutics Income Statement
| Year | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 | FY12 | FY11 | FY10 | FY09 | FY08 |
| Revenue | 233.18M | 145.24M | 212.02M | 227.49M | 198.32M | 175.34M | 164.25M | 154.94M | 133.59M | 99.89M | 28.2M | n/a | n/a | n/a | n/a | n/a | n/a |
| Cost of Revenue | n/a | 11.45M | 7.59M | 6.78M | 6.13M | 5.23M | 5.53M | 3.6M | 4.55M | 2.19M | 570.98K | n/a | n/a | n/a | n/a | n/a | n/a |
| Gross Profit | 233.18M | 133.79M | 204.43M | 220.71M | 192.19M | 170.1M | 158.72M | 151.33M | 129.04M | 97.71M | 27.63M | n/a | n/a | n/a | n/a | n/a | n/a |
| Operating Income | -320.63M | -376.74M | -251.56M | -139.5M | -75.38M | -99.81M | -80.04M | -53.79M | -58.21M | -50.75M | -79.81M | -23.97M | -30.24M | -12.82K | n/a | n/a | -18.27K |
| Interest Income | 17.82M | 21.77M | 6.28M | 1.99M | 5M | 10.05M | 5.5M | 700K | 3.98M | 7.75M | 7.43M | n/a | 21.83K | n/a | n/a | n/a | n/a |
| Pretax Income | -320.51M | -376.11M | -278.17M | -179.68M | -188.79M | -146.45M | -101.87M | -58.36M | -57.58M | 105.47M | -113.4M | -33.75M | -30.34M | -14.82K | n/a | n/a | -18.27K |
| Net Income | -321.55M | -111.4M | -278.48M | -180.09M | -169.43M | -146.43M | -102.68M | -59.73M | -47.9M | 117.24M | -110.94M | -33.82M | -30.34M | -14.82K | n/a | n/a | -18.27K |
| Selling & General & Admin | 264.12M | 265.54M | 220.21M | 149.88M | 135.8M | 128.95M | 103.65M | 103.96M | 98.02M | 79.54M | 59.64M | 16.89M | 30.26M | 12.82K | n/a | n/a | 13.43K |
| Research & Development | 217.5M | 244.99M | 235.78M | 210.33M | 131.77M | 140.96M | 123.76M | 78.17M | 70.85M | 50.43M | 47.8M | 7.08M | 662.5K | n/a | n/a | n/a | n/a |
| Other Expenses | 75.39M | n/a | 974K | 231K | 1.42M | -314K | -474K | 1.11M | -264K | -296K | 570.98M | n/a | 28.96B | n/a | n/a | n/a | n/a |
| Operating Expenses | 557M | 521.93M | 455.99M | 360.21M | 267.57M | 269.91M | 227.41M | 182.13M | 168.87M | 129.97M | 107.44M | 23.97M | 30.26M | 12.82K | n/a | n/a | 13.43K |
| Interest Expense | 11.18M | 11.33M | 11.28M | 20.14M | 19.05M | 18.83M | 9.81M | 1.19M | 34.48M | n/a | n/a | 19.5M | 105.92K | 2K | n/a | n/a | n/a |
| Selling & Marketing Expenses | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Cost & Expenses | 557M | 521.98M | 463.58M | 367M | 273.7M | 275.15M | 232.94M | 185.73M | 173.42M | 132.15M | 108.01M | 23.97M | 30.26M | 12.82K | n/a | n/a | 18.27K |
| Income Tax | 120K | 223K | 313K | 409K | -19.36M | -21K | 811K | 1.37M | -9.68M | -11.77M | -2.46M | 75.78K | 2.75K | n/a | n/a | n/a | n/a |
| Shares Outstanding (Basic) | 78.89M | 74.27M | 63.76M | 59.83M | 47.54M | 42.34M | 40.42M | 38.77M | 37M | 33.56M | 25.04M | 14.19M | 3.66M | 106.68K | n/a | n/a | 95.91M |
| Shares Outstanding (Diluted) | 78.89M | 74.27M | 63.76M | 59.83M | 47.54M | 42.34M | 40.43M | 38.77M | 38.29M | 37.58M | 25.06M | 14.21M | 3.66M | 106.68K | n/a | n/a | 95.91M |
| EPS (Basic) | -4.08 | -1.5 | -4.37 | -3.01 | -3.56 | -3.46 | -2.54 | -1.54 | -1.29 | 3.49 | -4.43 | -2.38 | -8.29 | -0.14 | n/a | n/a | -0.00 |
| EPS (Diluted) | -4.08 | -1.5 | -4.37 | -3.01 | -3.56 | -3.46 | -2.54 | -1.54 | -1.25 | 3.17 | -4.43 | -2.38 | -8.29 | -0.14 | n/a | n/a | -0.00 |
| EBITDA | -265.77M | -326.25M | -299.42M | -186.68M | -143.95M | -107.21M | -73.39M | -38.67M | -38.79M | 129.46M | -74.11M | -34.29M | -30.11M | -12.82K | n/a | n/a | -18.27K |
| Depreciation & Amortization | 43.55M | 38.53M | 20.72M | 26.62M | 25.79M | 20.41M | 18.67M | 17.8M | 16.14M | 13.39M | 5.4M | 215.99K | 124.89K | n/a | n/a | n/a | n/a |